Cargando…

Roles of four targets in the pathogenesis of graves' orbitopathy

Graves' orbitopathy (GO) is an autoimmune disease that involves complex immune systems. The mainstays of clinical management for this disease are surgery, targeted drugs therapy, and no-targeted drugs drug therapy. targeted drugs can improve therapeutic efficacy and enhance the quality of life...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Ziqiang, Zhang, Hailing, Yu, Haiwen, Zhu, Xiqiang, Lin, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558314/ https://www.ncbi.nlm.nih.gov/pubmed/37810014 http://dx.doi.org/10.1016/j.heliyon.2023.e19250

Ejemplares similares

The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves’ Orbitopathy
por: Byeon, Hyeong Ju, et al.
Publicado: (2023)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis?
por: Krieger, Christine C., et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2021)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves’ Orbitopathy
por: Kim, Bo Yi, et al.
Publicado: (2022)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
por: Supronik, Jakub, et al.
Publicado: (2022)

Tears as a Source of Biomarkers in the Diagnosis of Graves’ Orbitopathy
por: Bajkowska, Diana, et al.
Publicado: (2022)

Novel Roles of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy
por: Cui, Xuejiao, et al.
Publicado: (2023)

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy
por: Bartalena, Luigi
Publicado: (2022)

Imaging studies for diagnosing Graves' orbitopathy and dysthyroid optic neuropathy
por: Gonçalves, Allan C. Pieroni, et al.
Publicado: (2012)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure
por: Fan, Shu-Xian, et al.
Publicado: (2021)

A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves’ orbitopathy
por: Wang, Yue, et al.
Publicado: (2021)

Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy
por: Lin, Miaoli, et al.
Publicado: (2015)

Establishment and Comparison of Two Different Animal Models of Graves’ Orbitopathy
por: Wang, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vprdem0jpndgtp0umq9us1p6qm